Cost-Effectiveness of Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Single-Agent Pembrolizumab for High-Risk Early-Stage Triple-Negative Breast Cancer in the United States

INTRODUCTION: The randomized phase III KEYNOTE-522 trial demonstrated that addition of pembrolizumab to neoadjuvant chemotherapy provided a significant improvement in event-free survival and a favorable trend in overall survival for high-risk early-stage triple-negative breast cancer (eTNBC). This a...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Min, A. Fasching, Peter, Haiderali, Amin, Xue, Weiguang, Yang, Chelsey, Pan, Wilbur, Zhou, Zheng-Yi, Hu, Peter, Chaudhuri, Mitashri, Le Bailly De Tilleghem, Celine, Cappoen, Nicolas, O’Shaughnessy, Joyce
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9988745/
https://www.ncbi.nlm.nih.gov/pubmed/36648737
http://dx.doi.org/10.1007/s12325-022-02365-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9988745/
https://www.ncbi.nlm.nih.gov/pubmed/36648737
http://dx.doi.org/10.1007/s12325-022-02365-1

Ejemplares similares